Companies that use Dotcompliance

Source: Analysis of tech stacks from 176 companies that use Dotcompliance

I noticed Dotcompliance users operate in highly regulated industries, particularly life sciences and pharmaceuticals. The presence of Veeva Vault and Medidata Rave, both specialized tools for clinical trials and regulatory documentation, tells me these companies manage complex compliance requirements around drug development, clinical data, and regulatory submissions. The strong correlation with Salesforce CRM and Experience Cloud suggests they're selling to other businesses, likely managing intricate approval processes and stakeholder communications.

The pairing of Medidata Rave with Dotcompliance makes perfect sense because clinical trial data requires meticulous compliance tracking and audit trails. Benchling appearing alongside these tools suggests companies running both R&D lab operations and clinical trials, needing compliance documentation across the entire product development lifecycle. NetSuite's presence indicates mid-market to enterprise companies that need integrated financial management alongside their compliance workflows. These aren't startups but established organizations with significant operational complexity.

My analysis shows these are distinctly sales-led organizations in the growth to mature stage. The Salesforce Experience Cloud correlation points to companies managing partner portals or customer communities, which is common in pharma and biotech where you need to coordinate with investigators, research sites, and regulatory bodies. They're likely post-Series B or profitable companies with 100-500 employees who've moved beyond basic compliance spreadsheets to purpose-built systems. The combination of enterprise sales tools with specialized life sciences platforms suggests companies generating $20M+ in revenue.

Source: Analysis of Linkedin bios of 176 companies that use Dotcompliance

I noticed that Dotcompliance primarily serves life sciences companies that manufacture, develop, or deliver physical products requiring rigorous quality and regulatory oversight. The typical customer is developing pharmaceuticals, medical devices, biologics, or biotechnology solutions. These aren't purely software or services companies. They're making tangible things that go into human bodies or treating human patients, whether that's intraocular lenses, stent grafts, cell therapies, drug conjugates, or sterile pharmaceutical preparations.

These companies span the full maturity spectrum, though they lean toward clinical-stage and growth-phase organizations. I counted numerous Series A through Series D companies, several post-IPO entities, and some established manufacturers with 500-plus employees. The funding amounts range from small grants under $2 million to massive rounds exceeding $ million. Many describe themselves as "clinical-stage" or mention Phase 2 or Phase 3 trials, suggesting they're navigating the complex regulatory pathway toward commercialization.